| 大肠癌的靶向治疗 |
| |
| 引用本文： | 王肇炎,王尔兵. 大肠癌的靶向治疗[J]. 肿瘤研究与临床, 2006, 18(2): 73-75 |
| |
| 作者姓名： | 王肇炎 王尔兵 |
| |
| 作者单位： | 410006,湖南省肿瘤医院内科 |
| |
| 摘 要： | 阐述了贝伐单抗（BV）与西妥昔单抗（C225）治疗晚期或转移性大肠癌（CRC）的作用。分子靶向药物BV与C225能特异性阻断血管内皮生长因子（VEGF）和表皮生长因子受体（EGFR）的生物效应，临床应用治疗CRC有效且耐受良好，它与细胞毒药物不同，主要是抑制肿瘤生长，而不是缩小，与化疗联合应用可望增强疗效，延长生存期与改善生活质量。
|
| 关 键 词： | 贝伐单抗 西妥昔单抗 大肠癌 |
| 文章编号： | 1006-9801（2006）02-0073-03 |
| 收稿时间： | 2005-12-12 |
| 修稿时间： | 2005-12-27 |
Targeted therapy of colorectal cancer |
| |
| WANG Zhao-yan,WANG Er-bing. Targeted therapy of colorectal cancer[J]. Cancer Research and Clinic, 2006, 18(2): 73-75 |
| |
| Authors: | WANG Zhao-yan WANG Er-bing |
| |
| Affiliation: | Department of Internal medicine, Hunan Cancer Hospital, Changsha 410006, China |
| |
| Abstract: | This article reviews the role of bevacizumab (BV) and cetuximab (C225) in the treatment of the patients with advanced or metastatic colorectal cancer(CRC). The molecules targeting agents BV and C225 are being specifically blocking biological response of VEGF and EGFR. The clinical application of these agents for CRC is effective and well tolerated. Unlike traditional chemotherapy, it primarily inhibits tumor growth rather than regression. The combination of targeted agents (BV and C225) with cytotoxic agents holds the promise of enhanced chemotherapy benefits, prolonged survival and improved quality of life for patients with CRC |
| |
| Keywords: | Bevacizumab Cetuximab Colorectal cancer |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《肿瘤研究与临床》浏览原始摘要信息 |
|
点击此处可从《肿瘤研究与临床》下载免费的PDF全文 |
